Instrument Inactif

Communiqués ITUS Corp OTC Bulletin Board

Actions

ITUS

US45069V1044

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

19/08	Le vaccin de Moderna et Merck contre le mélanome en tête de la course au premier vaccin thérapeutique contre le cancer	RE
14/07	Anixa Biosciences, Inc. renforce son portefeuille mondial de brevets avec l'homologation d'un brevet en Australie pour sa technologie de vaccin contre le cancer du sein	CI

Communiqués

24/08	Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy	PR
18/08	Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference	PR
14/07	Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology	PR
06/07	Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date	PR
29/06	Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040	PR
29/06	Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial	AQ
26/06	Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium	PR
11/06	Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium	PR
01/06	Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance	PR
11/05	/C O R R E C T I O N -- Anixa Biosciences, Inc./	PR
01/05	Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV	PR
01/05	Anixia Biosciences and OwlTing Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV	AQ
29/04	Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology	PR
23/04	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell and Gene Therapy 2026 Annual Meeting	AQ
22/04	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting	PR
20/04	Replays from RedChip's Biotech Investor Conference Now Available	AQ
10/04	RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation	AQ
09/04	Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026	PR
07/04	Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026	PR
06/04	Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs	PR
01/04	Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing	PR
30/03	Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer	PR
12/03	Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast	PR
10/03	Anixa Biosciences : 2026 Annual Meeting of Shareholders Presentation	PU
09/03	Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology	PR